Dedifferentiation of differentiated thyroid carcinoma cell line FTC-133 is enhanced by 131I pretreatment

Nuclear Medicine and Biology

Volumn 38, Issue 7, 2011, Pages 1053-1058

  Feng, Fang ^a   Wang, Hui ^a   Fu, Hongliang ^a   Wu, Shuqi ^a   Ye, Zhiyi ^a   Chen, Suyun ^a   Li, Jianing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Dedifferentiation; Differentiated thyroid carcinoma; Follicular thyroid carcinoma; Nuclear medicine; Radioiodine

Indexed keywords

IODINE 131; MESSENGER RNA; METHYLTHIAZOL TETRAZOLIUM; SODIUM IODIDE SYMPORTER; TETRAZOLIUM; THYROGLOBULIN; THYROID PEROXIDASE; THYROTROPIN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; DOWN REGULATION; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG UPTAKE; HUMAN; HUMAN CELL; INCUBATION TIME; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BIOLOGICAL TRANSPORT; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IODIDE PEROXIDASE; IODINE RADIOISOTOPES; RECEPTORS, THYROTROPIN; RNA, MESSENGER; SYMPORTERS; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 80053616798     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.03.001     Document Type: Article

References (23)

1. Woodrum D.T., Gauger P.G. Role of 131I in the treatment of well differentiated thyroid cancer. J Surg Oncol 2005, 89:114-121.
2. Jeong H., Kim Y.R., Kim K.N., Choe J.G., Chung J.K., Kim M.K. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl Med Biol 2006, 33:875-882.
3. Walter M.A., Wild D., Rasch H., Müller-Brand J., Müller B., Bilz S. Coregistered iodine-131 single photon emission computed tomography/computed tomography reveals dedifferentiation in a metastatic follicular thyroid carcinoma. Thyroid 2006, 16:1063-1064.
4. Quiros R.M., Ding H.G., Gattuso P., Prinz R.A., Xu X. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 2005, 103:2261-2268.
5. Ringel M.D. Molecular markers of aggressiveness of thyroid cancer. Curr Opin Endocrinol Diabetes Obes 2009, 16:361-366.
6. Wang H.M., Huang Y.W., Huang J.S., Wang C.H., Kok V.C., Hung C.M., et al. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma. Ann Surg Oncol 2007, 14:3011-3018.
7. Tepmongkol S., Keelawat S., Honsawek S., Ruangvejvorachai P. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid 2008, 18:697-704.
8. Dai G., Levy O., Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996, 379:458-460.
9. Trouttet-Masson S., Selmi-Ruby S., Bernier-Valentin F., Porra V., Berger-Dutrieux N., Decaussin M., et al. Evidence for transcriptional and posttranscriptional alterations of the sodium/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors. Am J Pathol 2004, 165:25-34.
10. Kim W.G., Kim E.Y., Kim T.Y., Ryu J.S., Hong S.J., Kim W.B., et al. Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer. Endocr J 2009, 56:105-112.
11. Lee W.W., Lee B., Kim S.J., Jin J., Moon D.H., Lee H. Kinetics of iodide uptake and efflux in various human thyroid cancer cells by expressing sodium iodide symporter gene via a recombinant adenovirus. Oncol Rep 2003, 10:845-849.
12. Tuncel M., Aydin D., Yaman E., Tazebay U.H., Güç D., Doǧan A.L., et al. The comparative effects of gene modulators on thyroid-specific genes and radioiodine uptake. Cancer Biother Radiopharm 2007, 22:443-449.
13. Weiss S.J., Philp N.J., Grollman E.F. Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology 1984, 114:1090-1098.
14. Cholewinski S.P., Yoo K.S., Klieger P.S., O'Mara R.E. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. J Nucl Med 2000, 41:1198-1202.
15. Medvedec M. Thyroid stunning in vivo and in vitro. Nucl Med Commun 2005, 26:731-735.
16. Lundh C., Nordén M.M., Nilsson M., Forssell-Aronsson E. Reduced iodide transport (stunning) and DNA synthesis in thyrocytes exposed to low absorbed doses from 131I in vitro. J Nucl Med 2007, 48:481-486.
17. Lassmann M., Luster M., Hänscheid H., Reiners C. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 2004, 45:619-625.
18. Mian C., Barollo S., Pennelli G., Pavan N., Rugge M., Pelizzo M.R., et al. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf) 2008, 68:108-116.
19. Gérard A.C., Daumerie C., Mestdagh C., Gohy S., De Burbure C., Costagliola S., et al. Correlation between the loss of thyroglobulin iodination and the expression of thyroid-specific proteins involved in iodine metabolism in thyroid carcinomas. J Clin Endocrinol Metab 2003, 88:4977-4983.
20. Xing M., Usadel H., Cohen Y., Tokumaru Y., Guo Z., Westra W.B., et al. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res 2003, 63:2316-2321.
21. Hoffmann S., Maschuw K., Hassan I., Wunderlich A., Lingelbach S., Ramaswamy A., et al. Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells. Endocrine 2006, 30:129-138.
22. Lee Y.J., Chung J.K., Shin J.H., Kang J.H., Jeong J.M., Lee D.S., et al. In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene. Thyroid 2004, 14:889-895.
23. Huang M., Batra R.K., Kogai T., Lin Y.Q., Hershman J.M., Lichtenstein A., et al. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther 2001, 8:612-618.